CeriBell (CBLL) Expected to Post Earnings on Monday

CeriBell (NASDAQ:CBLL) will likely be announcing its Q2 2026 results after the market closes on Monday, August 10th. Analysts expect CeriBell to post earnings of ($0.45) per share and revenue of $27.2760 million for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Monday, August 10, 2026 at 4:30 PM ET.

CeriBell (NASDAQ:CBLL) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.13). CeriBell had a negative return on equity of 38.19% and a negative net margin of 63.51%.The business had revenue of $26.49 million for the quarter, compared to analysts’ expectations of $26.09 million. On average, analysts expect CeriBell to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

CeriBell Stock Performance

Shares of CBLL stock opened at $18.81 on Friday. The company’s fifty day simple moving average is $18.52 and its 200-day simple moving average is $19.11. The company has a market cap of $713.65 million, a PE ratio of -11.54 and a beta of 0.81. CeriBell has a 52 week low of $10.85 and a 52 week high of $24.33. The company has a current ratio of 10.44, a quick ratio of 10.01 and a debt-to-equity ratio of 0.14.

Insiders Place Their Bets

In other news, Director Joseph Michael Taylor sold 5,500 shares of the business’s stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $18.41, for a total transaction of $101,255.00. Following the completion of the transaction, the director owned 61,573 shares of the company’s stock, valued at approximately $1,133,558.93. The trade was a 8.20% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Tpg Gp A, Llc sold 202,368 shares of the business’s stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $20.12, for a total transaction of $4,071,644.16. Following the transaction, the insider directly owned 3,765,054 shares of the company’s stock, valued at $75,752,886.48. The trade was a 5.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 300,685 shares of company stock worth $5,935,326. Corporate insiders own 17.70% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Caitong International Asset Management Co. Ltd grew its holdings in CeriBell by 3,971.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock worth $28,000 after acquiring an additional 1,231 shares during the period. Tower Research Capital LLC TRC grew its stake in CeriBell by 353.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock valued at $43,000 after acquiring an additional 1,801 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of CeriBell in the third quarter worth approximately $33,000. Russell Investments Group Ltd. boosted its holdings in shares of CeriBell by 41.4% during the fourth quarter. Russell Investments Group Ltd. now owns 2,918 shares of the company’s stock worth $64,000 after purchasing an additional 854 shares during the period. Finally, New York State Common Retirement Fund grew its position in CeriBell by 148.6% during the second quarter. New York State Common Retirement Fund now owns 8,700 shares of the company’s stock valued at $163,000 after purchasing an additional 5,200 shares in the last quarter.

Analysts Set New Price Targets

CBLL has been the topic of several recent research reports. Canaccord Genuity Group reduced their price target on CeriBell from $28.00 to $25.00 and set a “buy” rating on the stock in a research report on Tuesday, May 12th. Weiss Ratings downgraded shares of CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 14th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, CeriBell currently has a consensus rating of “Moderate Buy” and an average target price of $22.20.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.